Exjade Association With Renal Failure Cited In FDA MedWatch Alert
This article was originally published in The Pink Sheet Daily
Executive Summary
Warnings and Adverse Reactions sections of labeling for Novartis’ oral iron overload treatment has been updated.
You may also be interested in...
Novartis Warns Doctors Of Hepatic Failure Cases With Exjade
Swiss drug maker notes that most cases were in patients with significant comorbidities.
Novartis Warns Doctors Of Hepatic Failure Cases With Exjade
Swiss drug maker notes that most cases were in patients with significant comorbidities.
Novartis Exjade Clears FDA As First Oral Chelating Agent
Novartis receives broad indication for deferasirox for treatment of iron overload in patients over 2 years of age.